Brentuximab vedotin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Brentuximab vedotin and local guidelines before prescribing.
Antibody-drug conjugate
Mechanism
CD30 antibody-drug conjugate.
Uses
Hodgkin lymphoma, anaplastic large-cell lymphoma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Peripheral neuropathy, neutropenia, infusion reactions, PML.
Interactions
Bleomycin contraindicated.
Contraindications and cautions
Concurrent bleomycin
Monitoring
FBC, neuropathy
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
Neuropathy reduces dose.
More from the textbook: uses, cautions and other points
- Advanced stage: ABVD with an interim PET-CT after 2 cycles . If PET-negative (Deauville 1–3) bleomycin is dropped (AVD) to reduce lung toxicity (RATHL trial); if PET-positive, treatment is escalated. Brentuximab vedotin-based regimens and BrECADD are used in some patients.
Haematology: Myeloma and Lymphoma - Brentuximab vedotin | Anti-CD30 drug conjugate for Hodgkin and ALCL; peripheral neuropathy; avoid with bleomycin (lung toxicity); rare PML.
Haematology: Myeloma and Lymphoma - Brentuximab vedotin (CD30) | Hodgkin's lymphoma, some T-cell lymphomas | Peripheral neuropathy, neutropenia
Haematology: Anatomy Physiology and Pharmacology - Relapse or refractory: salvage chemotherapy then autologous stem cell transplant ; brentuximab vedotin and PD-1 inhibitors (nivolumab, pembrolizumab).
Haematology: Myeloma and Lymphoma - Peripheral T-cell lymphoma including angioimmunoblastic (fever, rash, polyclonal hypergammaglobulinaemia, Coombs-positive haemolysis) and anaplastic large cell lymphoma (CD30+; ALK-positive cases have a better outlook; brentuximab vedotin with CHP).
Haematology: Myeloma and Lymphoma
Where it is discussed in the book
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Myeloma and Lymphoma (4 mentions)